IDT Biologika establishes new US base

Published: 2-Jun-2009
Media Packaging Pharmaceutical

IDT Biologika has opened new offices in Herndon, Virginia to serve pharmaceutical and biopharmaceutical customers in the US. It will be run by Peter Linzmeyer, executive vice president of IDT Biologika Corporation, a wholly owned subsidiary of IDT Biologika in Germany.


IDT Biologika has opened new offices in Herndon, Virginia to serve pharmaceutical and biopharmaceutical customers in the US. It will be run by Peter Linzmeyer, executive vice president of IDT Biologika Corporation, a wholly owned subsidiary of IDT Biologika in Germany.

IDT Biologika said it had expanded its business with multinational firms and seen increased demand for its fully integrated services in the US market.

The company operates one of Europe's leading integrated pharmaceutical and biological development and manufacturing facilities and opened new filling and packaging facilities at Dessau-Rosslau, Germany in January.

Dr Ralf Pfirmann, ceo of IDT Biologika, said the new US operation would enable the company to support its customers" operations in the US drug market and develop closer working relationships with firms in the region.

"The opening of a US location is a logical next step in our growth to become a global supplier of sterile liquid dosage forms," he added.

In addition to sterile liquid dosage forms, IDT Biologika uses the latest technologies in sterile production for vaccines, taking advantage of the operational expertise gained from many years of contract manufacturing.

IDT Biologika has invested more than Euro 200m in the last 15 years building the highly modern and efficient biopharmaceutical site at Dessau-Rosslau.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Read more
Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  3. Optimising the blending of flow aids in powder formulations Flow aids are used routinely in pharmaceutical manufacturing to enhance the process performance of powder blends and safeguard the critical quality attributes of finished products
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  5. AstraZeneca appoints Iskra Reic as its International Executive Vice President Iskra will be responsible for championing AstraZeneca's growth across key markets globally, as well as business strategy development

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Distribution

Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01

The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
Manufacturing

Novo Nordisk invests DKK 8.5bn into new Danish modular production site

This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Navigating challenges and charting the future of primary packaging for parenteral pharmaceuticals

Administering parenteral medications, a cornerstone of contemporary medical practice, entails injecting the drug either beneath the skin or directly into the circulatory system, reports Anna Malori, Head of Product Management at Bormioli Pharma
Packaging

Gerresheimer acquires Bormioli Pharma Group through Blitz LuxCo Sarl merger

Gerresheimer and Bormioli Pharma will merge to provide the biotech and pharmaceutical industries with primary packaging solutions, dosing systems, closure solutions and accessories
Manufacturing

Reckitt expands US OTC manufacturing footprint with North Carolina facility

The site in Wilson will be responsible for producing Mucinex® branded tablets and liquids, which are designed as over the counter (OTC) medicines for cold and flu symptoms
Subscribe now